M. Alexander Shaw to Lead Archimedic as CEO

After 15 years, Archimedic is experiencing a change in leadership.

The company has appointed M. Alexander Shaw, Ph.D., as CEO, succeeding Eric Sugalski, who has led the firm since its founding. Dr. Shaw will help Archimedic partner with companies to transform novel technologies into market-ready products that address technical, regulatory, usability, and commercial needs.
 
“Dr. Shaw’s medical product development expertise combined with his experience in successfully leading and growing a life-science consulting business makes him a perfect fit for helping Archimedic achieve its next phase of growth,” Sugalski said.
 
With Shaw at the helm, Sugalski will become chief technology officer, leveraging his extensive background in engineering, regulatory affairs, and commercial strategy to help clients advance their technologies into market-focused, derisked solutions. “I am excited to be stepping into this hands-on role working directly with our team and clients to advance new medical technologies,” Sugalski stated.
 
Bringing 15-years of leadership experience in biotech and pharma consulting, Dr. Shaw was formerly the chief operating officer of Nuventra Pharma Sciences, where he co-led the company from inception into a stable, revenue generating business prior to its sale in May 2021. He co-developed Nuventra Pharma Sciences from a two-person boutique clinical pharmacology consulting shop into a 125-person full-service drug development consulting group with $22 million in annual revenue.

Dr. Shaw earned dual bachelor’s degrees in chemistry and biology from Duke University, followed by his Ph.D. in biochemistry and Biophysics from Washington State University. He went on to an American Heart Association post-doctoral fellowship at the University of Pennsylvania. 

“Archimedic’s demonstrated expertise in all three major segments of medical device development: design, regulatory affairs, and commercialization, provides real value to its clients, greatly improving their chances for successful commercialization of their products and bringing necessary advances to the medical field,” Dr. Shaw commented.
 
Since 2009, Archimedic has been helping companies develop drug delivery, surgical, diagnostic, and home health medical devices. Helping medtech innovators transform napkin sketch concepts into market-ready medical devices, Archimedic’s work is advancing cancer care, preventing hip fractures, improving outcomes for extremely premature infants, reducing the cost of life-changing drugs, and more. Archimedic helps companies with product development, quality and regulatory affairs, and commercialization strategy.